Paul Calabresi Award in Clinical Oncology Research

项目总结/摘要 保罗·卡拉布雷西临床肿瘤学研究奖（PCACOR）竞争性更新的理由 申请是继续准备高素质的癌症临床研究人员，所谓的学者，谁将 成为独立的领导者。这些临床研究领导者将满足对训练有素的 进行关键癌症临床试验和/或关键临床相关研究的院士， 从实验室到床边的持续翻译。通过这一独特的培训计划和我们的专业知识， 导师，学者将成功地学习沟通和协调多学科团队， 科学家和应用不断增长的科学知识量个性化癌症治疗。具体 目标是：1）为每个学者选择一个灵活的个人发展计划， 多学科咨询委员会，申请人可能是接受过肿瘤学培训的医学博士、博士临床医生 完成临床培训或博士水平的基础科学家致力于学术癌症事业， 重临床重点; 2）通过有意的跨学科培训，沟通和互动 团队指导和定期的以学者为中心的会议，成功培养完成PCACOR学者 过渡到独立; 3）创建一个由训练有素的临床研究领导者组成的多元化队列， 将运行新颖的，创新的多学科研究议程，将我们目前的科学转化为 减轻癌症负担。此外，这些训练有素的思想领袖将成为正在进行的 新学员的辅导周期。PCACOR的设计结合了我们的特殊教师， 强大的导师，他们将在非常丰富的支持环境中提供卓越的培训和榜样 来自科罗拉多大学癌症中心。经验丰富的项目负责人是Madeleine A。Kane，医学博士，哲学博士 和弗吉尼亚F. Borges，MD，MMSC，两位教授都有丰富的相关经验。定制化培训 为期两到五年，包括一系列学者定制教学的核心要求 课程作业，学者设计的主要研究项目的至少一个癌症临床试验或辅助研究。 培训期间将侧重于每个学者的具体个人培训需求， 通过辅导环境获得这些所需技能将确保向独立过渡。作为一种结果， 所有学者在第三年前提交NIH或同等资助。最终的成功是 我们的业绩记录证明了这一点共有22名初级教师接受了PCACOR学者的培训， 在目前的资助期间（24个申请中的7个）。18名学者是教师， 科罗拉多大学丹佛安舒茨医学院（UCD-AMC）; 14人获得晋升，所有人都有 多篇同行评审的出版物。18个获得了来自NIH，DOD，ACS的同行评审资金 和/或疾病基础。所有人都设计了至少一项癌症临床试验， 癌症临床试验我们的PCACOR成功地培养了 现在和未来

Project Summary/Abstract The rationale of this Paul Calabresi Award in Clinical Oncology Research (PCACOR) competitive renewal application is to continue to prepare highly qualified cancer clinical researchers, called Scholars, who will become independent leaders. These clinical research leaders will meet the ongoing need for highly trained academicians running pivotal cancer clinical trials and/or the critical clinical correlative studies that will inform ongoing translation from bench to bedside. Through this unique training program and the expertise of our mentors, the Scholars will succeed in learning to communicate and coordinate multidisciplinary teams of scientists and apply the ever growing amount of scientific knowledge to personalize cancer treatment. Specific objectives are to: 1) Design a flexible Individual Development Program for each Scholar selected by the Multidisciplinary Advisory Committee from applicants who may be oncology trained MDs, PhD clinicians with completed clinical training or PhD level basic scientists committed to an academic cancer career with heavy clinical focus; 2) Foster interdisciplinary training, communication and interaction through intentional team mentoring and regular Scholar-centered meetings, creating completed PCACOR Scholars successfully transitioned to independence; 3) Create a diverse cohort of highly trained clinical research leaders that will run novel, innovative multidisciplinary research agendas to move the translational of our current science to reduce the burden of cancer. Also, these highly trained thought leaders will become part of the ongoing mentorship cycle back to new trainees. The PCACOR design incorporates our exceptional faculty as strong mentors who will provide exceptional training and role models in the very richly supported environment of the University of Colorado Cancer Center. Experienced Program Leaders are Madeleine A. Kane, MD, PhD and Virginia F. Borges, MD, MMSc, both Professors with extensive relevant experience. The tailored Training Period lasts from two to five years and includes Core Requirements of a selection of Scholar tailored didactic coursework, a Scholar designed major research project of at least one cancer clinical trial or ancillary study. The Training Period will focus on the specific individual training needs of each Scholar for which mastery of these needed skills through the mentored environment will ensure transition to independence. As an outcomes metric, all Scholars submit an NIH or equivalent grant by the third year. The ultimate success is demonstrated by our track record. A total of twenty-two junior faculty have trained as PCACOR Scholars, seven during the current funding period (out of 24 applications). Eighteen Scholars are faculty members at University of Colorado Denver Anschutz Medical Campus (UCD-AMC); fourteen have been promoted, all have multiple peer-reviewed publications. Eighteen have obtained peer-reviewed funding from NIH, DOD, ACS and/or disease-based foundations. All have designed at least one cancer clinical trial, and several lead national cancer clinical trials. Our PCACOR successfully produces the translational cancer clinical researchers of now and the future.